NCT06658938View on ClinicalTrials.gov

Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions
B-ALL
Interventions
DRUG

Blinatumomab

"Beginning 3 months after transplantation, 1 cycle of blinatumomab was performed every 3 months for a total of 4 maintenance cycles.~Dosage of blinatumomab: 9 ug/d D1-4, 28 ug/d D5-14"

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06658938 - Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter